文献速递肿瘤 PET/CT

重复动态[18F]FDG PET/CT成像使用高灵敏度PET/CT扫描仪评估接受诱导免疫化疗后行低分次放化疗及巩固免疫治疗的非小细胞肺癌患者:前瞻性观察研究(GASTO-1067)报告

Repeated dynamic [18F]FDG PET/CT imaging using a high-sensitivity PET/CT scanner for assessing non-small cell lung cancer patients undergoing induction immuno-chemotherapy followed by hypo-fractionated chemoradiotherapy and consolidative immunotherapy: report from a prospective observational study (GASTO-1067).
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-07-02

本前瞻性观察研究纳入15例不可切除的局部晚期非小细胞肺癌(LA-NSCLC)患者,在四个时间点行动态[18F]FDG PET/CT,评估原发肿瘤代谢特征与免疫组化及血液淋巴细胞的关系。基线Patlak-Ki预测疾病进展和死亡的AUC分别为0.722和0.796;高FDG Ki组(Ki > 2.779 ml/min/100 g,n=8)较低FDG Ki组(Ki ≤ 2.779 ml/min/100 g,n=7)有更好的无进展生存(P=0.01)和总生存(P=0.025)。

要点

  • 基线原发肿瘤Patlak-Ki预测疾病进展AUC为0.722,预测死亡AUC为0.796。
  • 高FDG Ki组(n=8)较低FDG Ki组(n=7)无进展生存P=0.01、总生存P=0.025更优。
  • 高FDG Ki组肿瘤组织CD3+ T细胞(P=0.003)、CD8+ T细胞(P=0.002)、CD163+巨噬细胞(P=0.012)更高。

核心结论

  • 高FDG Ki组代谢特征在治疗期间显著下降,尤其在诱导免疫化疗后。
  • 原发肿瘤Ki值与接受联合免疫放化疗的LA-NSCLC患者治疗反应和生存显著相关。

研究设计与样本

  • 前瞻性观察研究,纳入15例不可切除的LA-NSCLC患者,招募时间为2020年12月至2022年12月。
  • 在四个时间点(治疗前基线、诱导免疫化疗后、低分次放化疗期间、低分次放化疗后)行高灵敏度PET/CT扫描仪动态[18F]FDG PET/CT。
  • 手动勾画原发肺部肿瘤,评估Patlak-Ki、最大SUV、代谢肿瘤体积和总病灶糖酵解。
  • 基线原发肿瘤组织免疫组化检测CD3、CD8、CD68、CD163、CD34和Ki67表达。
  • 四个时间点用流式细胞术分析血液淋巴细胞水平。

主要发现

  • 基线原发肿瘤Ki预测疾病进展AUC为0.722,预测患者死亡AUC为0.796。
  • 高FDG Ki组(n=8,Ki > 2.779 ml/min/100 g)无进展生存P=0.01、总生存P=0.025优于低FDG Ki组(n=7,Ki ≤ 2.779 ml/min/100 g)。
  • 高FDG Ki组低分次放化疗后Ki下降较低FDG Ki组更显著。
  • Ki下降 > 73.1%者无进展生存优于Ki下降 ≤ 73.1%者(中位:未达到 vs. 7.33个月,P=0.12)。
  • 高FDG Ki组原发肿瘤组织CD3+ T细胞(P=0.003)、CD8+ T细胞(P=0.002)、CD68+巨噬细胞(P=0.071)、CD163+巨噬细胞(P=0.012)水平更高。

关键数值与推荐

  • 高FDG Ki组定义为Ki > 2.779 ml/min/100 g(n=8),低FDG Ki组定义为Ki ≤ 2.779 ml/min/100 g(n=7)。
  • Ki下降 > 73.1%者无进展生存优于Ki下降 ≤ 73.1%者(中位:未达到 vs. 7.33个月,P=0.12)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The study aims to investigate the role of dynamic [18F]FDG PET/CT imaging by high-sensitivity PET/CT scanner for assessing patients with locally advanced non-small cell lung cancer (LA-NSCLC) who undergo induction immuno-chemotherapy, followed by concurrent hypo-fractionated chemoradiotherapy (hypo-CCRT) and consolidative immunotherapy. METHODS: Patients with unresectable LA-NSCLC are prospectively recruited. Dynamic [18F]FDG PET/CT scans are conducted at four timepoints: before treatment (Baseline), after induction immuno-chemotherapy (Post-IC), during hypo-CCRT (Mid-hypo-CCRT) and after hypo-CCRT (Post-hypo-CCRT). The primary lung tumors (PTs) are manually delineated, and the metabolic features, including the Patlak-Ki (Ki), maximum SUV (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) have been evaluated. The expressions of CD3, CD8, CD68, CD163, CD34 and Ki67 in primary lung tumors at baseline are assayed by immunohistochemistry. The levels of blood lymphocytes at four timepoints are analyzed with flow cytometry. RESULTS: Fifteen LA-NSCLC patients are enrolled between December 2020 and December 2022. Baseline Ki of primary tumor yields the highest AUC values of 0.722 and 0.796 for predicting disease progression and patient death, respectively. Patients are classified into the High FDG Ki group (n = 8, Ki > 2.779 ml/min/100 g) and the Low FDG Ki group (n = 7, Ki ≤ 2.779 ml/min/100 g). The High FDG Ki group presents better progression-free survival (P = 0.01) and overall survival (P = 0.025). The High FDG Ki group exhibits more significant reductions in Ki after hypo-CCRT compared to the Low FDG Ki group. Patients with a reduction in Ki > 73.1% exhibit better progression-free survival than those with a reduction ≤ 73.1% in Ki (median: not reached vs. 7.33 months, P = 0.12). The levels of CD3+ T cells (P = 0.003), CD8+ T cells (P = 0.002), CD68+ macrophages (P = 0.071) and CD163+ macrophages (P = 0.012) in primary tumor tissues are higher in the High FDG Ki group. The High FDG Ki group has higher CD3+CD8+ lymphocytes in blood at baseline (P = 0.108), post-IC (P = 0.023) and post-hypo-CCRT (P = 0.041) than the Low FDG Ki group. CONCLUSIONS: The metabolic features in the High FDG Ki group significantly decrease during the treatment, particularly after induction immuno-chemotherapy. The Ki value of primary tumor shows significant relationship with the treatment response and survival in LA-NSCLC patients by the combined immuno-chemoradiotherapy regimen. TRIAL REGISTRATION: ClinicalTrials.gov. NCT04654234. Registered 4 December 2020.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wang D, Mo Y, Liu F, et al. Repeated dynamic [18F]FDG PET/CT imaging using a high-sensitivity PET/CT scanner for assessing non-small cell lung cancer patients undergoing induction immuno-chemotherapy followed by hypo-fractionated chemoradiotherapy and consolidative immunotherapy: report from a prospective observational study (GASTO-1067). Eur J Nucl Med Mol Imaging. 2024. PMID: 38953934. doi:10.1007/s00259-024-06819-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。